Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1515/cclm-2020-1413 http://scihub22266oqcxt.onion/10.1515/cclm-2020-1413 33027043!ä!33027043 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Chem+Lab+Med 2020 ; 58 (12): 2001-2008 Nephropedia Template TP {{tp|p=33027043|t=2020. IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2 |pdf=|usr=}}{{33027043}} gab.com Text IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2 JO: Clin Chem Lab Med http://www.kidney.de/pget.php?&tw=1&pmid=33027043 #FOAvip Serological testing for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as an important component of the clinical management of patients with coronavirus disease 2019 (COVID-19) as well as the epidemiological assessment of SARS-CoV-2 exposure worldwide. In addition to molecular testing for the detection of SARS-CoV-2 infection, clinical laboratories have also needed to increase testing capacity to include serological evaluation of patients with suspected or known COVID-19. While regulatory approved serological immunoassays are now widely available from diagnostic manufacturers globally, there is significant debate regarding the clinical utility of these tests, as well as their clinical and analytical performance requirements prior to application. This document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Taskforce on COVID-19 provides interim guidance on: (A) clinical indications and target populations, (B) assay selection, (C) assay evaluation, and (D) test interpretation and limitations for serological testing of antibodies against SARS-CoV-2 infection. These evidence-based recommendations will provide practical guidance to clinical laboratories in the selection, verification, and implementation of serological assays and are of the utmost importance as we expand our pandemic response from initial case tracing and containment to mitigation strategies to minimize resurgence and further morbidity and mortality. Twit Text FOAVip IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2 ????Clin Chem Lab Med http://www.kidney.de/pget.php?&tw=1&pmid=33027043 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33027043 #FOAvip English Wikipedia <ref>{{Cite pmid|33027043}}</ref> IFCC Interim Guidelines on Serological Testing of Antibodies against SARS-CoV-2 #MMPMID33027043 Bohn MK; Loh TP; Wang CB; Mueller R; Koch D; Sethi S; Rawlinson WD; Clementi M; Erasmus R; Leportier M; Grimmler M; Yuen KY; Mancini N; Kwon GC; Menezes ME; Patru MM; Gramegna M; Singh K; Najjar O; Ferrari M; Horvath AR; Lippi G; Adeli K Clin Chem Lab Med 2020[Oct]; 58 (12): 2001-2008 PMID33027043show ga Serological testing for the detection of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as an important component of the clinical management of patients with coronavirus disease 2019 (COVID-19) as well as the epidemiological assessment of SARS-CoV-2 exposure worldwide. In addition to molecular testing for the detection of SARS-CoV-2 infection, clinical laboratories have also needed to increase testing capacity to include serological evaluation of patients with suspected or known COVID-19. While regulatory approved serological immunoassays are now widely available from diagnostic manufacturers globally, there is significant debate regarding the clinical utility of these tests, as well as their clinical and analytical performance requirements prior to application. This document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Taskforce on COVID-19 provides interim guidance on: (A) clinical indications and target populations, (B) assay selection, (C) assay evaluation, and (D) test interpretation and limitations for serological testing of antibodies against SARS-CoV-2 infection. These evidence-based recommendations will provide practical guidance to clinical laboratories in the selection, verification, and implementation of serological assays and are of the utmost importance as we expand our pandemic response from initial case tracing and containment to mitigation strategies to minimize resurgence and further morbidity and mortality. |*International Agencies[MESH] |*Practice Guidelines as Topic[MESH] |Antibodies, Viral/*blood/immunology[MESH] |Betacoronavirus/*immunology[MESH] |Humans[MESH] |SARS-CoV-2[MESH]IFCC Interim Guidelines on Serological Testing of Antibodies against S(epmc).pdf DeepDyve Pubget Overpricing